In contrast, ERK1/2 stimulation by growth factors or other protective compounds as well as preconditioning may prevent ischemic damage through different pathways as they also prevent the release of ERK1/2 triggers such as reactive oxygen species or pro-inflammatory cytokines that are known to induce adverse outcomes in stroke [6]. The gene discussed is MAPK3; the disease is stroke disorder.